时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Zlotta2 , Cosimo de Nunzio 8 , Firas Abdollah 9 , Jonathan Evan Shoag10 , Spyridon Basourakos10 , Frederico Ferronha11 , Andrea Cosenza 5,12 , Christopher Wallis2 , Quoc-Dien Trinh12 , Neil Fleshner2 , Jihad Kaouk 1 and Riccardo Autorino 1 ✉ © The Author(s) 2026 BACKGROUND: Prostate cancer epidemiology is evolving because of three simultaneous factors: a rising global burden, population aging, and renewed debate about how early detection can reduce advanced disease without returning to non-risk-adapted PSA testing.；Prostate Cancer and Prostatic Diseases; https://doi.org/10.1038/s41391-026-01167-8 INTRODUCTION The epidemiology of prostate cancer is being reshaped by a rising global burden, population aging, and renewed debate over how early detection can reduce advanced disease without reverting to indiscriminate PSA testing.
方法
METHODS: We synthesized recent systematic reviews, meta-analyses, randomized screening trials, and population-based registry data, supplemented by landmark historical studies.；We searched PubMed/ MEDLINE and, where relevant, Embase for English-language articles published up to June 2026, using combinations of the terms “prostate cancer,” “epidemiology,” “incidence,” “mortality,” “prevalence,” “risk factors,” “screening,” “PSA,” “MRI,” and “dispa- rities.” We prioritized (i) contemporary international guidelines, (ii) large randomized controlled trials and their long-term follow-up, (iii) population-based registry analyses and pooled/multi-cohort studies, and (iv) recent systematic reviews and meta-analyses, supplemented by landmark historical studies where they remain foundational.
核心结论
CONCLUSIONS: Progress will depend on preventing metastatic disease, minimizing overtreatment, and implementing modern diagnostics equitably.；These trends show that prostate cancer epidemiology cannot be separated from early-detection policy, and they support risk-adapted approaches, including biomarker- informed pathways and MRI, applied equitably across higher-risk populations.；Consequently, age-related mortality rates have decreased substantially over the last three decades in North America [6], Europe [7] and other high income countries of Australasia [8]. ‖ 结论：CONCLUSION By 2026, prostate cancer epidemiology reflects how health systems detect and manage disease as much as biology itself.
局限
Incidence, mortality and prevalence GLOBOCAN 2022 shows marked geographic heterogeneity in incidence and mortality across Europe (473,011 cases; 115,182 deaths), Asia (386,424; 120,485), North America (255,782; 39,605), Latin America/Caribbean (225,985; 61,056), Africa (103,050; 55,744), and Oceania (23,602; 5358) [1].；Most modifiable exposures, by contrast, rest on observational data of uncertain causality and are more appropriately situated within general cardiometabolic health than framed as prostate cancer–specific preventive targets, while a residual group remains hypothesis-generating.；Where randomized and observational estimates are considered jointly, we specify the design and evidenti
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。设计 systematic review。
全文来源
出版商 OA PDF（正文 76,518 字符，已过 DOI 逐字 / 标题指纹归属校验）
原文题录
- 英文标题：Prostate cancer worldwide: updated epidemiology, disparities, and screening implications.
- 期刊与标识：Prostate Cancer Prostatic Dis · PMID 42946767 · DOI 10.1038/s41391-026-01167-8
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。